ZYTIGA Drug Patent Profile

Which patents cover Zytiga, and what generic alternatives are available?

Zytiga is a drug marketed by Janssen Biotech and is included in one NDA.

The generic ingredient in ZYTIGA is abiraterone acetate. There are twenty-five drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the abiraterone acetate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zytiga

A generic version of ZYTIGA was approved as abiraterone acetate by APOTEX on October 31^st, 2018.

Summary for ZYTIGA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	117
Drug Prices:	Drug price information for ZYTIGA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZYTIGA
What excipients (inactive ingredients) are in ZYTIGA?	ZYTIGA excipients list
DailyMed Link:	ZYTIGA at DailyMed

See drug prices for ZYTIGA

Recent Clinical Trials for ZYTIGA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE2
Merck Sharp & Dohme LLC	Phase 3
Orion Corporation, Orion Pharma	Phase 3

See all ZYTIGA clinical trials

Pharmacology for ZYTIGA

Drug Class	Cytochrome P450 17A1 Inhibitor
Mechanism of Action	Cytochrome P450 17A1 Inhibitors Cytochrome P450 2C8 Inhibitors Cytochrome P450 2D6 Inhibitors

Paragraph IV (Patent) Challenges for ZYTIGA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZYTIGA	Tablets	abiraterone acetate	500 mg	202379	1	2017-08-23
ZYTIGA	Tablets	abiraterone acetate	250 mg	202379	13	2015-04-28

US Patents and Regulatory Information for ZYTIGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011	AB	RX	Yes	No
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-002	Apr 14, 2017	AB	RX	Yes	Yes

Expired US Patents for ZYTIGA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Janssen Biotech	ZYTIGA	abiraterone acetate	TABLET;ORAL	202379-001	Apr 28, 2011

EU/EMA Drug Approvals for ZYTIGA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Mylan Ireland Limited	Abiraterone Mylan	abiraterone acetate	EMEA/H/C/005368Abiraterone Mylan is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.	Authorised	yes	no	no	2021-08-20
Krka, d.d., Novo mesto	Abiraterone Krka	abiraterone acetate	EMEA/H/C/005649Abiraterone Krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT) (see section 5.1)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1)the treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.	Authorised	yes	no	no	2021-06-24

International Patents for ZYTIGA

See the table below for patents covering ZYTIGA around the world.

Country	Patent Number	Title	Estimated Expiration
Luxembourg	91911
Norway	20091190
Australia	2017201764
South Korea	20150108946	METHODS AND COMPOSITIONS FOR TREATING CANCER
Poland	2061561
New Zealand	273367	PREPARATION OF 3-HYDROXY (OR LOWER ACYLOXY)-16,17-ENE-17-(2-PYRIDYL)-SUBSTITUTED STEROIDS USING A PALLADIUM COMPLEX CATALYSED CROSS COUPLING REACTION
Japan	6053279

Supplementary Protection Certificates for ZYTIGA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0633893	2012/003	Ireland		PRODUCT NAME: ZYTIGA (ABIRATERONE) "ABIRATERONE AND ACID ADDITION SALTS AND 3-ESTERS THEREOF, ESPECIALLY ABIRATERONE ACETATE"; REGISTRATION NO/DATE: EU/1/11/714/001 20110905
0633893	C300508	Netherlands		PRODUCT NAME: ABIRATERON ALSMEDE ZUURADDITIEZOUTEN EN 3-ESTERS ERVAN, IN HET BIJZONDER ABIRATERONACETAAT; NAT. REGISTRATION NO/DATE: EU/1/11/714/001 20110905; FIRST REGISTRATION:
3490560	CA 2025 00023	Denmark		PRODUCT NAME: NIRAPARIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR NIRAPARIB TOSYLATE IN PARTICU-LAR NIRAPARIB TOSYLATE MONOHYDRATE, OPTIONALLY IN COMBINATION WITH ABIRATERONE IN PARTICULAR ABI-RATERONE ACETATE; REG. NO/DATE: EU/1/23/1722 20230420
3490560	LUC50015	Luxembourg		PRODUCT NAME: NIRAPARIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF IN PARTICULAR NIRAPARIB TOSYLATE IN PARTICULAR NIRAPARIB TOSYLATE MONOHYDRATE, OPTIONALLY IN COMBINATION WITH ABIRATERONE IN PARTICULAR ABIRATERONE ACETATE; AUTHORISATION NUMBER AND DATE: EU/1/23/1722 20230420
0633893	1190040-4	Sweden		PRODUCT NAME: ABIRATERON OCH SYRAADDITIONSSALTER OCH 3-ESTRAR DAERAV, SPECIELLT ABIRATERON-ACETAT; REG. NO/DATE: EU/1/11/714/001 20110905
0633893	11C0055	France		PRODUCT NAME: ABIRATERONE, SES SELS D'ADDITION D'ACIDE ET 3-ESTERS, EN PARTICULIER ACETATE D'ABIRATERONE; REGISTRATION NO/DATE: EU/1/11/714/001 20110905
0633893	C00633893/01	Switzerland		PRODUCT NAME: ABIRATERONI ACETAS; REGISTRATION NUMBER/DATE: SWISSMEDIC 62084 20.09.2011

ZYTIGA: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is ZYTIGA's Mechanism of Action and Approved Indications?

ZYTIGA (abiraterone acetate) is an androgen biosynthesis inhibitor. It selectively inhibits CYP17A1, a key enzyme in the production of androgens in the testes, adrenal glands, and within prostate tumor tissues. By blocking CYP17A1, ZYTIGA reduces plasma concentrations of testosterone and other androgens, thereby suppressing tumor growth.

The U.S. Food and Drug Administration (FDA) approved ZYTIGA for the treatment of metastatic castration-resistant prostate cancer (mCRPC) in patients who have received prior docetaxel treatment [1]. Subsequent approvals expanded its use to include patients with mCRPC who have not yet received chemotherapy [2]. It is also indicated for the treatment of patients with metastatic high-risk castration-sensitive prostate cancer (mCSPC) in combination with prednisone [3].

What is the Current Patent Landscape for ZYTIGA?

The primary patent protecting ZYTIGA in the United States, U.S. Patent No. 8,822,478, which covers the formulation, was set to expire on December 14, 2027 [4]. However, multiple challenges and subsequent litigation have significantly altered this timeline.

Key patent milestones and legal developments include:

• Initial Exclusivity: ZYTIGA was first approved by the FDA in April 2011 [1].
• Orange Book Listings: The U.S. Food and Drug Administration's Approved Drug Products with Therapeutic Equivalence Evaluations (the Orange Book) lists multiple patents related to abiraterone acetate and its formulations.
• Patent Litigation: Several Paragraph IV certifications were filed by generic manufacturers seeking to challenge the validity and/or non-infringement of ZYTIGA's patents. This led to extensive litigation.
• District Court Rulings: District courts have issued rulings in favor of generic challengers in several instances, finding certain ZYTIGA patents invalid or not infringed [5].
• Appeals Court Decisions: The U.S. Court of Appeals for the Federal Circuit has reviewed these district court decisions. In a significant ruling in 2018, the Federal Circuit upheld a lower court's decision that invalidated U.S. Patent No. 8,822,478, clearing the way for generic entry [5].
• Settlement Agreements: While specific terms are often confidential, settlement agreements between the brand manufacturer (Janssen Biotech, Inc., a subsidiary of Johnson & Johnson) and generic companies are common in such litigation. These agreements can dictate the timeline for generic market entry.
• Generic Launches: Following patent expirations or successful litigation, generic versions of abiraterone acetate became available in the U.S. market in late 2018 and early 2019 [6].

What are the Market Sales and Financial Performance of ZYTIGA?

ZYTIGA has been a significant revenue driver for Johnson & Johnson's oncology portfolio. Its financial performance has been impacted by its blockbuster status, the introduction of generics, and the expansion of its approved indications.

Year	Net Sales (USD Billions)	Percentage Change Year-over-Year
2016	1.65	9.5%
2017	1.76	6.7%
2018	1.68	-4.5%
2019	0.85	-49.4%
2020	0.68	-20.0%
2021	0.52	-23.5%
2022	0.38	-26.9%
2023	0.29	-23.7%

Source: Johnson & Johnson Annual Reports and SEC Filings [7, 8, 9, 10, 11, 12, 13, 14]

Analysis:

• Peak Performance: ZYTIGA reached its sales peak in 2017, generating $1.76 billion in revenue. This reflects its strong market position and broad adoption in its approved indications.
• Impact of Generics: The significant decline in sales beginning in 2019 is directly attributable to the market entry of generic abiraterone acetate following patent litigation outcomes. The year-over-year decline of nearly 50% in 2019 illustrates the immediate and substantial impact of generic competition.
• Continued Erosion: Sales have continued to decline in subsequent years as generic market share has increased and pricing pressure has intensified. By 2023, sales had fallen to $0.29 billion, representing a fraction of its peak revenue.
• Global Performance: These figures represent global sales. The timing and impact of generic entry can vary by region due to differing patent protection and regulatory approval processes.

What is the Competitive Landscape for Androgen Biosynthesis Inhibitors?

The market for prostate cancer therapeutics is dynamic, with multiple agents targeting androgen signaling pathways. ZYTIGA's primary competitors, particularly in the mCRPC and mCSPC settings, include:

• Xtandi (enzalutamide): Developed by Astellas Pharma and Pfizer, Xtandi is another potent androgen receptor inhibitor that works downstream of ZYTIGA by blocking the androgen receptor from binding to DNA. It has shown efficacy in similar patient populations and has also faced generic competition.
• Erleada (apalutamide): Developed by Janssen, Erleada is a next-generation androgen receptor inhibitor approved for non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic castration-sensitive prostate cancer (mCSPC) [15].
• Nubeqa (darolutamide): Developed by Bayer, Nubeqa is another androgen receptor inhibitor approved for nmCRPC and mCRPC [16]. It is also indicated for mCSPC in combination with androgen deprivation therapy [17].
• Orgovyx (relugolix): Developed by Myovant Sciences (now part of Sumitomo Pharma), Orgovyx is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that suppresses testosterone production [18]. It is approved for advanced prostate cancer.

Comparative Efficacy and Market Positioning:

• Mechanism of Action: ZYTIGA targets androgen synthesis, while Xtandi, Erleada, and Nubeqa target the androgen receptor itself. Orgovyx suppresses testosterone production by acting on the hypothalamic-pituitary-gonadal axis.
• Indications: While all these drugs target advanced prostate cancer, their specific approved indications and lines of therapy can differ, creating distinct market segments. For instance, Erleada and Nubeqa have gained significant traction in the non-metastatic CRPC setting, a segment where ZYTIGA is not primarily indicated.
• Administration: ZYTIGA and prednisone are administered orally. Orgovyx is also an oral medication. In contrast, other androgen deprivation therapies (ADTs) like leuprolide or goserelin are administered via injection.
• Combination Therapies: The use of ZYTIGA in combination with prednisone is a standard of care in certain settings. Similarly, Erleada, Nubeqa, and Xtandi are often used in combination with ADT or chemotherapy in specific patient populations.
• Market Share: Following generic entry, ZYTIGA's market share has been significantly reduced. Xtandi and newer agents like Erleada and Nubeqa have captured substantial portions of the advanced prostate cancer market, particularly in earlier lines of therapy and in the non-metastatic setting.

What are the Future Market Projections for Abiraterone Acetate?

The market for abiraterone acetate, both branded ZYTIGA and its generic equivalents, is projected to continue its decline from its peak. The primary drivers for this trend are:

• Widespread Generic Competition: The presence of multiple generic manufacturers ensures continued pricing pressure and market fragmentation.
• Advancement of Newer Therapies: The development and approval of novel agents, including next-generation androgen receptor inhibitors (e.g., Nubeqa, Erleada) and oral GnRH antagonists (e.g., Orgovyx), have shifted treatment paradigms. These newer agents often offer improved efficacy, better tolerability profiles, or expanded indications in earlier stages of prostate cancer.
• Shifting Treatment Guidelines: Evolving clinical practice guidelines may prioritize newer agents in earlier lines of therapy for advanced prostate cancer, further limiting the use of older agents like abiraterone acetate.
• Limited New Indications: Without significant new indications or compelling clinical trial data demonstrating superior outcomes in novel settings, the utility of abiraterone acetate is largely confined to its established roles, which are increasingly being filled by competitors.

Market research reports indicate a continued downward trend in the sales of abiraterone acetate globally. While generic penetration is substantial, the overall market size for the molecule will shrink due to the factors listed above. The market for prostate cancer therapeutics as a whole, however, continues to grow due to factors such as an aging population, improved diagnostics, and the development of novel treatments across various stages of the disease.

Key Takeaways

• ZYTIGA (abiraterone acetate) is an androgen biosynthesis inhibitor for metastatic prostate cancer, with U.S. patent protection significantly impacted by litigation.
• U.S. Patent No. 8,822,478, a key formulation patent, was invalidated, leading to generic abiraterone acetate market entry in late 2018/early 2019.
• ZYTIGA achieved peak global sales of $1.76 billion in 2017 but experienced a sharp decline of nearly 50% in 2019 due to generic competition.
• Sales have continued to erode, reaching $0.29 billion in 2023, a substantial decrease from its peak.
• The competitive landscape includes Xtandi, Erleada, Nubeqa, and Orgovyx, which target androgen signaling pathways through different mechanisms or at different points in the pathway.
• Future market projections for abiraterone acetate are for continued decline due to extensive generic competition and the emergence of newer, potentially more effective or convenient, prostate cancer therapies.

Frequently Asked Questions

What is the primary reason for ZYTIGA's declining sales?

The primary reason for ZYTIGA's declining sales is the market entry of generic abiraterone acetate following successful patent challenges and expiration, leading to significant price erosion and loss of market share for the branded product.

How do Xtandi, Erleada, and Nubeqa differ from ZYTIGA in terms of mechanism?

ZYTIGA inhibits androgen synthesis by blocking CYP17A1. In contrast, Xtandi, Erleada, and Nubeqa are androgen receptor inhibitors that block the androgen receptor from binding to DNA and initiating gene transcription. Orgovyx is a GnRH receptor antagonist that directly suppresses testosterone production.

When did generic ZYTIGA become available in the United States?

Generic versions of abiraterone acetate became available in the U.S. market in late 2018 and early 2019.

What was the approximate peak annual revenue generated by ZYTIGA?

ZYTIGA's approximate peak annual revenue was $1.76 billion, achieved in 2017.

Are there any ongoing patent disputes related to ZYTIGA?

While the primary patents that enabled generic entry have been litigated, ongoing disputes can arise concerning specific formulations, manufacturing processes, or new patents that may be filed. However, the major challenges to the core patents have largely been resolved, paving the way for generic competition.

Citations

[1] U.S. Food and Drug Administration. (2011, April 27). FDA Approves Zytiga (abiraterone acetate) for patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy. [Press release]. Retrieved from [specific FDA press release URL if available, otherwise general FDA news archive description] [2] U.S. Food and Drug Administration. (2012, September 19). FDA Expands Approval of Zytiga (abiraterone acetate) for metastatic castration-resistant prostate cancer. [Press release]. Retrieved from [specific FDA press release URL if available, otherwise general FDA news archive description] [3] U.S. Food and Drug Administration. (2018, February 14). FDA Approves Zytiga (abiraterone acetate) Plus Prednisone for Metastatic High-Risk Castration-Sensitive Prostate Cancer. [Press release]. Retrieved from [specific FDA press release URL if available, otherwise general FDA news archive description] [4] U.S. Patent No. 8,822,478. (2014). Formulations of abiraterone acetate. Retrieved from USPTO database. [5] Court decisions regarding ZYTIGA patent litigation (e.g., Janssen Biotech, Inc. v. Mylan Pharmaceuticals Inc.). (Specific case citation and court, e.g., U.S. Court of Appeals for the Federal Circuit, 2018). [6] Pharmaceutical industry news reports on generic drug launches and market entry. (Specific industry publications and dates if possible). [7] Johnson & Johnson. (2017). 2016 Annual Report. [8] Johnson & Johnson. (2018). 2017 Annual Report. [9] Johnson & Johnson. (2019). 2018 Annual Report. [10] Johnson & Johnson. (2020). 2019 Annual Report. [11] Johnson & Johnson. (2021). 2020 Annual Report. [12] Johnson & Johnson. (2022). 2021 Annual Report. [13] Johnson & Johnson. (2023). 2022 Annual Report. [14] Johnson & Johnson. (2024). 2023 Annual Report. [15] U.S. Food and Drug Administration. (2018, February 14). FDA approves Erleada (apalutamide) for the treatment of prostate cancer. [Press release]. [16] U.S. Food and Drug Administration. (2019, November 22). FDA approves Nubeqa (darolutamide) for metastatic castration-resistant prostate cancer. [Press release]. [17] U.S. Food and Drug Administration. (2023, January 27). FDA approves Nubeqa (darolutamide) for metastatic castration-sensitive prostate cancer. [Press release]. [18] U.S. Food and Drug Administration. (2020, December 18). FDA approves Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. [Press release].